Sign in
Not yet taking people in South KoreaNo phase

Tests a smart insulin pen with glucose-sensor coaching in diabetes

Tests a smart insulin pen with coaching in adults with type 1 or 2 diabetes.

Key facts

Who runs it
G2e Co., Ltd
Where
Seoul, South KoreaSee the site
Trial code
Registry title
A Study of DIA:CONN P8 Smart Insulin Pen With CGM-Based Coaching in Patients With Type 1 or Type 2 Diabetes
Status
Not yet recruiting
People taking part
152 people, planned
Started
Jun 2025
Expected to end
Dec 2026
Type of study
Interventional, 2 groupsOne group gets no study treatment, for comparison.
Treatments tested
  • Smart Coaching Insulin Pen
Record updated
4 June 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 19 to 75 with type 1 or type 2 diabetes who use multiple daily insulin injections and have HbA1c of 7.5% (58 mmol/mol) to 12.0% (108 mmol/mol).

Age
19 to 75 years
Sex
All sexes can join.
Disease stage
Type 1 or type 2 diabetes diagnosed at least 1 year before screening. HbA1c of 7.5% (58 mmol/mol) to 12.0% (108 mmol/mol) at screening.
Earlier treatment
Must have used multiple daily insulin injections (MDI) for at least 3 months before screening, for example long-acting insulin plus rapid- or short-acting insulin, or mixed insulin at least 3 times per day.
Biomarker or test result
HbA1c of 7.5% (58 mmol/mol) to 12.0% (108 mmol/mol) at screening.

Main reasons for not taking part

  • Diabetes caused by removal of part of the pancreas
  • Corticosteroids above a prednisolone-equivalent dose of 5 mg/day within 3 months before screening (stable dose for at least 3 months may be allowed)
  • eGFR below 15 mL/min at screening or receiving dialysis
  • Pregnant or breastfeeding women

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • Age between 19 and 75 years old
  • Diagnosis of type 1 or type 2 diabetes for at least 1 year prior to screening
  • Continuous use of MDI therapy for at least 3 months prior to screening, defined as one of the following regimens:; Long-acting insulin plus rapid-/short-acting insulin; Mixed insulin (e.g., insulin aspart/insulin degludec) plus rapid-/short-acting insulin; Mixed insulin ≥3 times per day
  • HbA1c of 7.5% to 12.0% at screening

Who cannot take part

  • Use of corticosteroids exceeding a prednisolone-equivalent dose of 5 mg/day within 3 months prior to screening (Subjects on a stable dose for ≥3 months prior to screening may be eligible)
  • Diabetes mellitus secondary to pancreatic resection
  • eGFR <15 mL/min at screening or those receiving dialysis
  • Pregnant or lactating women

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 19 and 75 years old?

Where in South Korea

  • Samsung Medical CenterSeoul, South KoreaContact: SANGMAN JINNot yet recruiting

About the trial

What the trial wants to find out

A Study of DIA:CONN P8 Smart Insulin Pen With CGM-Based Coaching in Patients With Type 1 or Type 2 Diabetes

The 2 groups in the trial

  • Investigational GroupTreatment being tested

    Basal and bolus insulin injection using an electric smart insulin pen (DIA:CONN P8); equipped with a Setup-wizard, CGM-based Advanced insulin injection Coaching and a Bolus calculator \- Providing education on Carb Counting(carbohydrate measurement) and Methods for adjusting insulin bolus calculator

    Treatment: Smart Coaching Insulin Pen

  • Control groupNo study treatment, for comparison

    Basal and bolus insulin injection using only the injection and recording functions of DIA:CONN P8 \- Subjects manually enter and inject their insulin doses without using the bolus calculator or coaching functions

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Multicenter, Open Label, Randomized, Comparative Confirmatory Study to Evaluate the Efficacy and Safety of Electric Smart Insulin Pen (DIA:CONN P8) Including Setup Wizard, Advanced Insulin Injection Coaching and Bolus Calculator With Analysis Function Based on Continuous Glucose Monitoring Data in Patients With Type 1 or Type 2 Diabetes Mellitus Under Multiple Dose Insulin Therapy
Plain-language title
Tests a smart insulin pen with glucose-sensor coaching in diabetesGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT07004153, who can take part
Publications
Record updated
4 June 2025